| Literature DB >> 36090604 |
Jinglan Lai1, Yuming Liu2, Hanhui Ye1, Yahong Chen1.
Abstract
Purpose: This study aimed to investigate the epidemiology and etiological spectrums of BSI in Fujian over the past 6 years in the post antiretroviral treatment (ART) era.Entities:
Keywords: HIV; Talaromyces marneffei; bloodstream infection; epidemiology; etiology
Year: 2022 PMID: 36090604 PMCID: PMC9462516 DOI: 10.2147/IDR.S379100
Source DB: PubMed Journal: Infect Drug Resist ISSN: 1178-6973 Impact factor: 4.177
Figure 1Flow chart of bloodstream infections screening.
Baseline Characteristics in HIV Hospitalized Patients with Bloodstream Infection (N = 646)
| Variables | 2015 (n = 21) | 2016 (n = 66) | 2017 (n = 93) | 2018 (n = 154) | 2019 (n = 133) | 2020 (n = 116) | 2021 (n = 63) | All (n = 646) | P |
|---|---|---|---|---|---|---|---|---|---|
| Age (y), median (range) | 37 (21–69) | 36 (19–72) | 35 (18–88) | 37 (18–75) | 41 (20–89) | 39 (18–74) | 39 (21–77) | 38 (18–89) | 0.038 |
| Male (n, %) | 20 (95.24) | 55 (83.33) | 80 (86.02) | 129 (83.77) | 120 (90.23) | 101 (87.07) | 56 (88.89) | 561 (86.84) | 0.595 |
| CD4 (cells/µL), median (range) | 12 (1–240) | 14 (1–269) | 12 (1–1003) | 14 (0–660) | 16 (1–579) | 18 (1–709) | 12 (1–173) | 14 (0–1003) | 0.246 |
| >200 (n, %) | 1 (4.76) | 3 (4.55) | 5 (5.38) | 7 (4.55) | 7 (5.26) | 7 (6.03) | 0 (0) | 30 (4.64) | |
| <200 (n, %) | 20 (95.24) | 63 (95.45) | 88 (94.62) | 147 (95.45) | 126 (94.74) | 109 (93.97) | 63 (100) | 616 (95.36) | |
| CD8 (cells/µL), median (range) | 227 (141–1397) | 353 (119–1674) | 284 (45–1895) | 269 (28–1627) | 285 (22–2548) | 247 (14–1169) | 153 (23–1421) | 268 (14–2548) | <0.0001 |
| HIVRNA (IU/mL) | 0.001 | ||||||||
| <1×105 (n, %) | 5 (23.81) | 19 (28.79) | 52 (55.91) | 52 (33.77) | 37 (27.82) | 40 (34.48) | 19 (30.16) | 224 (34.67) | |
| >1×105 (n, %) | 16 (76.19) | 47 (71.21) | 41 (44.09) | 102 (66.23) | 96 (72.18) | 76 (65.51) | 44 (69.84) | 422 (65.33) | |
| PCT (ng/mL), median (range) | 0.64 (0.03–100) | 0.23 (0.04–7.88) | 0.07 (0.02–154.07) | 0.11 (0.02–82.93) | 0.14 (0.02–100) | 0.13 (0.02–54.93) | 0.11 (0.04–100) | 0.12 (0.02–154.07) | <0.0001 |
| CRP (mg/L), median (range) | 3.12 (0.91–237.02) | 8.12 (0.45–150.74) | 7.46 (0.43–279.59) | 8.01 (0.35–259.34) | 9.34 (0.2–225.29) | 7.68 (0.2–284.04) | 8.59 (0.27–250.61) | 8.57 (0.2–284.04) | 0.451 |
Notes: Quantitative variables are presented as the median (range). Categorical variables are presented as numbers (percentage). n: sample numbers.
Characteristics of Bloodstream Infection Among Inpatients with HIV
| Admission Patients (n) | Blood-Cultured Patients (n) | Culture-Positive Patients (n) | Culture Positive Rate (%) | Contamination Rate (%) | Polymicrobial Rate (%) | |
|---|---|---|---|---|---|---|
| 2015 | 204 | 136 | 21 | 15.44 | 0.74 | 1.47 |
| 2016 | 631 | 566 | 66 | 11.66 | 1.06 | 0.35 |
| 2017 | 700 | 587 | 93 | 15.84 | 3.41 | 0.85 |
| 2018 | 849 | 720 | 154 | 21.39 | 1.11 | 0.97 |
| 2019 | 798 | 684 | 133 | 19.44 | 2.05 | 0.58 |
| 2020 | 664 | 569 | 116 | 20.21 | 0.88 | 1.23 |
| 2021 | 436 | 419 | 63 | 15.04 | 2.15 | 1.67 |
| Total | 4282 | 3681 | 646 | 17.55 | 1.71 | 0.92 |
The Isolation Rate of Microorganisms in Bloodstream Infection Patients
| Year | Microorganisms (n,%) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Total | TM | Cryp | Myco | Stap | Stre | Ente | Asps | Cand | Others | |
| 2015 | 23 (16.91) | 16 (11.76) | 5 (3.68) | – | – | – | 1 (0.74) | – | – | 1 (0.74) |
| 2016 | 68 (12.01) | 47 (8.3) | 8 (1.41) | – | 3 (0.53) | – | 7 (1.24) | – | – | 3 (0.53) |
| 2017 | 100 (17.04) | 64 (10.90) | 19 (3.24) | – | 6 (1.02) | 2 (0.34) | 5 (0.85) | – | 1 (0.17) | 3 (0.51) |
| 2018 | 161 (22.36) | 108 (15.00) | 24 (3.33) | 5 (0.69) | 7 (0.97) | 2 (0.28) | 10 (1.39) | – | 1 (0.14) | 4 (0.56) |
| 2019 | 138 (20.18) | 87 (12.72) | 20 (2.92) | 8 (1.17) | 5 (0.73) | – | 15 (2.19) | – | 2 (0.29) | 1 (0.15) |
| 2020 | 123 (21.62) | 85 (14.94) | 14 (2.46) | 5 (0.88) | 5 (0.88) | – | 10 (1.76) | 1 (0.18) | 2 (0.35) | 1 (0.18) |
| 2021 | 70 (16.71) | 50 (11.93) | 7 (1.67) | 10 (2.39) | – | – | 2 (0.48) | – | 1 (0.24) | – |
| All | 683 (18.55) | 457 (12.42) | 97 (2.64) | 28 (0.76) | 26 (0.71) | 4 (0.11) | 50 (1.36) | 1 (0.03) | 7 (0.19) | 13 (0.35) |
Abbreviations: TM, Talaromyces marneffei; Cryp, Cryptococcus neoformans; Myco, Mycobacterium spp. (including Nontuberculous mycobacteria and Mycobacterium tuberculosis); Stap, Staphylococcus spp. (including Coagulase negative staphylococcus and Staphylococcus aureus); Stre, Streptococcus spp.; Ente, Enterobacterium spp.; Aspe, Aspergillus; Cand, Candida; Others, microorganisms except above.
The Composition of Microorganisms Isolated from Blood Culture (N = 683)
| Year | Microorganisms (n, %) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| TM | Cryp | Myco | Stap | Stre | Ente | Aspe | Cand | Others | |
| 2015 | 16 (69.57) | 5 (21.74) | – | – | – | 1 (4.34) | – | – | 1 (4.34) |
| 2016 | 47 (69.12) | 8 (11.76) | – | 3 (4.41) | – | 7 (10.29) | – | – | 3 (4.41) |
| 2017 | 64 (64.00) | 19 (19.00) | – | 6 (6.00) | 2 (2.00) | 5 (5.00) | – | 1 (1.00) | 3(3.00) |
| 2018 | 108 (67.08) | 24 (14.90) | 5 (3.10) | 7 (4.35) | 2 (1.24) | 10(6.21) | – | 1 (0.62) | 4(2.48) |
| 2019 | 87 (63.04) | 20 (14.49) | 8 (5.79) | 5 (3.62) | – | 15 (10.87) | – | 2 (1.45) | 1(0.72) |
| 2020 | 85 (69.11) | 14 (11.38) | 5 (4.07) | 5 (4.07) | – | 10 (8.13) | 1 (0.81) | 2 (1.63) | 1(0.81) |
| 2021 | 50 (71.43) | 7 (10.00) | 10 (14.29) | – | – | 2 (2.86) | – | 1 (1.43) | – |
| All | 457 (66.91) | 97 (14.20) | 28 (4.10) | 26 (3.81) | 4 (0.59) | 50 (7.32) | 1 (0.15) | 7 (1.02) | 13(1.90) |
Abbreviations: TM, Talaromyces marneffei; Cryp, Cryptococcus neoformans; Myco, Mycobacterium spp. (including Nontuberculous mycobacteria and Mycobacterium tuberculosis); Stap, Staphylococcus spp. (including Coagulase negative staphylococcus and Staphylococcus aureus); Stre, Streptococcus spp.; Ente, Enterobacterium spp.; Aspe, Aspergillus; Cand, Candida; Others, microorganism except above.
Comparison Between Patients with TM BSI and Other Pathogens BSI
| Group A | Group B | Z/χ2 | P | |
|---|---|---|---|---|
| Age>50y (n,%) | 93 (20.35) | 78 (34.51) | 16.162 | <0.0001 |
| Male (%) | 402 (87.96) | 187 (82.74) | 3.474 | 0.062 |
| CD4<200cells/µL (%) | 439 (96.06) | 200 (88.50) | 14.361 | <0.0001 |
| HIVRNA>1×104IU/mL (%) | 398 (87.09) | 155 (68.58) | 33.604 | <0.0001 |
| CRP (g/L), median(range) | 8.44 (0.3–279.59) | 10.14 (0.27–284.04) | −2.505 | 0.012 |
| PCT (ng/mL), median(range) | 0.13 (0.02–225.11) | 0.14 (0.02–154.07) | −0.516 | 0.606 |
| WBC (×109/L), median(range) | 3.54 (0.66–18.62) | 4.13 (0.29–42.28) | −3.652 | <0.0001 |
| HB (g/L), median(range) | 92 (41–144) | 97 (50–174) | −2.842 | 0.004 |
| PLT (×109/L), median(range) | 171 (3–552) | 181 (7–864) | −1.14 | 0.254 |
| ALT (U/L), median(range) | 27 (3–278) | 26 (3–664) | −0.869 | 0.385 |
| AST (U/L), median(range) | 30 (8–1999) | 29 (6–1999) | −0.730 | 0.465 |
| Cr (µmol/L), median(range) | 68 (10–610) | 67.5 (31–611) | −0.505 | 0.614 |
| BUN (mg/dL), median(range) | 4.70 (1–60) | 4.95 (0–34) | −0.443 | 0.658 |
Notes: Group A: Talaromyces marneffei group; Group B: other pathogens except Talaromyces marneffei; Z: Mann–Whitney test; χ2: Pearson Chi-square test.